Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial - Naomi B. Haas, Haas Nb, Judith Manola, Wong Yn, Robert G. Uzzo, Uzzo Rg, Keith T. Flaherty, Flaherty Kt, Christopher G. Wood, Wood Cg, Christopher Kane, Michael Jewett, Janice P. Dutcher, Michael B. Atkins, Dutcher Jp - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, The Lancet, 10032(387), p. 2008-2016, 2016

DOI: 10.1016/s0140-6736(16)00559-6

Links

Tools

Export citation

Search in Google Scholar

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Journal article published in 2016 by Naomi B. Haas, Haas Nb, Judith Manola, Wong Yn, Robert G. Uzzo, Uzzo Rg, Keith T. Flaherty, Flaherty Kt, Christopher G. Wood, Wood Cg, Christopher Kane, Michael Jewett, Janice P. Dutcher, Michael B. Atkins, Dutcher Jp and other authors.

This paper is available in a repository.

This paper is available in a repository.

Full text: Download

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO